Baricitinib: A Review in Severe Alopecia Areata
June 2023
in “American Journal of Clinical Dermatology”
TLDR Baricitinib helps regrow hair in severe alopecia areata but has side effects like infections and headaches.
Baricitinib, a Janus kinase (JAK) inhibitor, is the first drug approved in the USA and the EU for treating severe alopecia areata. Two phase 3 clinical trials involving adults with severe alopecia areata showed that daily oral baricitinib led to significant hair regrowth on the scalp, eyebrows, and eyelashes over a period of 36 weeks. However, it was associated with side effects such as infections, headaches, acne, and elevated levels of creatine phosphokinase. While more long-term data is required to fully understand its benefits and risks, current data suggests that baricitinib is a beneficial treatment for patients with severe alopecia areata.
View this study on link.springer.com →
Cited in this study
research Efficacy in Subgroups Related to Disease Characteristics in Patients with Alopecia Areata from BRAVE-AA1 and BRAVE-AA2
The study titled "44096 Efficacy in Subgroups related to Disease Characteristics in Patients with Alopecia Areata from BRAVE-AA1 and BRAVE-AA2" evaluated the efficacy of baricitinib, an oral JAK1/JAK2 inhibitor, in treating adults with severe alopecia areata (AA). The results from the BRAVE-AA1 and BRAVE-AA2 trials demonstrated that baricitinib significantly improved hair regrowth in patients with AA, regardless of disease characteristics. The trials included a substantial number of participants, providing robust evidence for the effectiveness of baricitinib in this patient population. These findings support the use of baricitinib as a treatment option for severe AA in the US, Europe, and Japan.
research Improvements in Health-Related Quality of Life and Psychological Symptoms in Patients With Severe Alopecia Areata Achieving Scalp Hair Regrowth: Results From Two Randomized Controlled Trials
research Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2
Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.
research Trajectories for Scalp Hair Regrowth in Patients With Severe Alopecia Areata Treated With Baricitinib
Baricitinib helps patients with severe alopecia areata regrow hair.
research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials
Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
research Integrated Safety Analysis of Baricitinib in Adults With Severe Alopecia Areata From Two Randomized Clinical Trials
Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
research Efficacy and Safety of Baricitinib in Adult Patients With Severe Alopecia Areata With or Without an Atopic Background From Two Randomized, Placebo-Controlled, Phase 3 Trials
Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
research An Overview of JAK/STAT Pathways and JAK Inhibition in Alopecia Areata
Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.
research Two Phase 3 Trials of Baricitinib for Alopecia Areata
Baricitinib was effective in treating alopecia areata in two major trials.
research Alopecia areata – Current understanding and management
Alopecia areata is a chronic condition causing hair loss, with new treatments targeting the immune system showing promise.
research Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
Baricitinib is effective and safe for treating severe alopecia areata.
research Alopecia Areata Treatment Patterns, Healthcare Resource Utilization, and Comorbidities in the US Population Using Insurance Claims
Most people with Alopecia Areata don't get treatment within a year; it's costly and often comes with other health issues.
research A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
JAK inhibitors show promise in effectively treating hair loss from alopecia areata.
research Epidemiology and burden of alopecia areata: a systematic review
Alopecia areata is a common autoimmune disease affecting about 2% of people, causing significant disability and often associated with mental health issues and other autoimmune conditions.
Related
research The Usefulness and Wellbeing of Tofacitinib in the Treatment of Alopecia Areata
Tofacitinib is effective and safe for treating alopecia areata.
research Alopecia areata universalis in a dog
A dog with complete hair loss regrew most hair after treatment, with no relapse after stopping treatment.
research PUVA treatment of alopecia areata totalis and universalis: A retrospective study
research Hypertrichosis due to minoxidil
Minoxidil causes excessive hair growth in almost all patients.